In this executive podcast discussion, MIKE CELENTANO talks to industry experts about RFID,
how e-pedigree legislation will shape the future and what it all means for pharma.
Dave Champagne was named Vice President and General Manager of Thermo Fisher Scientific Informatics business in April 2005. He joined Thermo in April 2003 as Director of Global Services for Informatics, and was later promoted to Commercial Director for the company’s Informatics and Services division.
p. Ranganath Nayak, Ph.D., Chief Executive Officer of Cytel Inc.,
gives insight into the adaptive clinical trials process.
BARBARA A. PALDUS, MARK SELKER and ALFY RIDDLE,
from Finesse, discuss changes in bioprocessing.
Aaron McCormack, CEO of BT Conferencing, shares how BT Conferencing offers solutions
for better communication among professionals in the pharmaceuticals and biotech industries.
There are widely agreed upon areas where eClinical technology solutions are expected to have the largest impact. The first is to dramatically reduce costs...
Future Pharmaceuticals: There is a lot of talk in the industry about the need for the pharmaceutical business model to change.
If you're using standards, interchange and transferring data becomes easier. You're not spending time converting from one format to another. Therefore, your processes change because you've introduced standards.
In order to provide high-quality solutions for critical healthcare needs around the world, Ira Spector of Wyeth Research believes clinical trials must go global.
Adaptive designs have the potential to improve the information value of the experiment: our ambition is to make the correct decision at the earliest possible time point (and no earlier).
The future of the pharmaceutical industry is being driven by the need to not only introduce safe and effective drugs and medical
devices, but to do so in the face of exceptionally demanding economic pressure and competition. Striving to meet these needs has been both challenging and rewarding for eRT.
Michael KramS M.D.,
Assistant Vice President of
Adaptive Trials within the Clinical
Trials Development Organization,
Wyeth, discusses the evolving nature
of adaptive clinical trial design.
Shahram Hejazi Ph.D., President, Carestream Molecular Imaging, a division of Carestream Health Inc., engages in a discussion about the rapid development optical molecular imaging technologies and the impact of these developments.
Devin Leake, Ph.D., explains how Thermo Fisher Scientific is taking strides ahead in RNAi research.
Madhu Sharma Ph.D., Research Analyst, Drug Discovery Technologies and Clinical Diagnostics, Frost ; Sullivan, enlightens readers about the advances in flow cytometry.